Ignite Creation Date:
2025-12-24 @ 4:57 PM
Ignite Modification Date:
2025-12-30 @ 1:10 PM
Study NCT ID:
NCT05017350
Status:
UNKNOWN
Last Update Posted:
2021-08-23
First Post:
2021-08-03
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Hemostasis Using Radiofrequency Ablation for Track Bleeding
Sponsor:
Kyoung Doo Song
Organization:
Study Overview
Official Title:
Hemostasis Using Radiofrequency Ablation for Track Bleeding After Liver Biopsy
Status:
UNKNOWN
Status Verified Date:
2021-08
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study aims to evaluate the usefulness of hemostasis using radiofrequency ablation for track bleeding that has occurred after percutaneous biopsy of the liver.
Detailed Description:
Purpose: To evaluate the usefulness of hemostasis using radiofrequency ablation for track bleeding after percutaneous liver biopsy.
Method:
* Enroll patients who continue to bleed despite conservative treatment for track bleeding that has occurred after liver biopsy.
* Radiofreqeuncy ablation: Under monitoring vital signs and controlling pain with intravenous agents, the electrode is inserted into the bleeding focus. The bleeding focus is ablated.
* Hemostasis is evaluated by ultrasound (right after radiofrequency ablation), CT scan (after the radiofrequency ablation), and ultrasound (the day after radiofrequency ablation)
* If hemostasis fails using radiofrequency ablation, transarterial hepatic embolization is performed immediately.
Method:
* Enroll patients who continue to bleed despite conservative treatment for track bleeding that has occurred after liver biopsy.
* Radiofreqeuncy ablation: Under monitoring vital signs and controlling pain with intravenous agents, the electrode is inserted into the bleeding focus. The bleeding focus is ablated.
* Hemostasis is evaluated by ultrasound (right after radiofrequency ablation), CT scan (after the radiofrequency ablation), and ultrasound (the day after radiofrequency ablation)
* If hemostasis fails using radiofrequency ablation, transarterial hepatic embolization is performed immediately.
Study Oversight
Has Oversight DMC:
True
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: